Clinical Trial

Use of Pyrvinium to Reverse Stomach Precancerous Conditions

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is carried out to find out if a drug called pyrvinium is able to convert pre-cancerous tissue in the stomach back to healthy tissue, to lower the chances of stomach cancer. Pyrvinium is a drug that has been used for a long time to treat pinworms in children and its anti-cancer properties are currently under investigation. Tests in animals have shown that pyrvinium made unhealthy tissue healthier and stopped some cells from growing in a bad way. Based on preclinical studies, the investigators hypothesise that the proportion of samples with pre-cancerous tissue in the stomach would decrease by 50% after exposure to pyrvinium at the 6-week timepoint, with anticipated durability of the response at the one-year follow-up.
Trial Details
NCT Number NCT06782048
Lead Sponsor National University Hospital, Singapore
Collaborators: National University of Singapore, Vanderbilt University Medical Center
Conditions STOMACH NEOPLASM
Enrollment 50 participants
Start Date 2025-08
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-17